A detailed history of Alliancebernstein L.P. transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 40,630 shares of STOK stock, worth $488,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,630
Previous 40,630 -0.0%
Holding current value
$488,778
Previous $548,000 8.94%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.03 - $17.52 $36,288 - $57,640
3,290 Added 8.81%
40,630 $548,000
Q4 2023

Feb 14, 2024

SELL
$3.37 - $5.4 $13,412 - $21,492
-3,980 Reduced 9.63%
37,340 $196,000
Q2 2023

Aug 15, 2023

BUY
$7.93 - $13.82 $51,703 - $90,106
6,520 Added 18.74%
41,320 $439,000
Q1 2023

May 15, 2023

BUY
$7.65 - $10.38 $33,660 - $45,672
4,400 Added 14.47%
34,800 $289,000
Q4 2022

Feb 14, 2023

BUY
$7.07 - $15.69 $20,503 - $45,501
2,900 Added 10.55%
30,400 $280,000
Q3 2022

Nov 15, 2022

BUY
$12.56 - $22.53 $47,728 - $85,614
3,800 Added 16.03%
27,500 $353,000
Q2 2022

Aug 15, 2022

BUY
$10.36 - $23.93 $40,404 - $93,327
3,900 Added 19.7%
23,700 $313,000
Q4 2021

Feb 14, 2022

BUY
$18.11 - $30.72 $21,732 - $36,864
1,200 Added 6.45%
19,800 $475,000
Q3 2021

Nov 10, 2021

SELL
$23.65 - $34.44 $28,380 - $41,328
-1,200 Reduced 6.06%
18,600 $473,000
Q2 2021

Jul 30, 2021

BUY
$30.53 - $41.09 $51,901 - $69,853
1,700 Added 9.39%
19,800 $666,000
Q1 2021

May 06, 2021

BUY
$36.08 - $69.81 $25,256 - $48,867
700 Added 4.02%
18,100 $703,000
Q4 2020

Feb 08, 2021

SELL
$33.62 - $61.93 $110,945 - $204,369
-3,300 Reduced 15.94%
17,400 $1.08 Million
Q3 2020

Nov 12, 2020

SELL
$22.23 - $37.48 $26,676 - $44,975
-1,200 Reduced 5.48%
20,700 $693,000
Q2 2020

Aug 13, 2020

BUY
$20.26 - $29.73 $93,196 - $136,758
4,600 Added 26.59%
21,900 $522,000
Q1 2020

May 14, 2020

BUY
$16.8 - $34.15 $290,640 - $590,795
17,300 New
17,300 $396,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $474M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.